Triumvira Immunologics establishes collaboration with Merck to evaluate TAC01-HER2 in combination with KEYTRUDA®

On January 5, 2023, Triumvira Immunologics, Inc. (“Triumvira”) announced a clinical trial collaboration and supply agreement with Merck (known as MSD outside the U.S. and Canada). Triumvira's ongoing TACTIC-2 trial will evaluate the use of its novel autologous cell therapy TAC01-HER2 as a monotherapy but also in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of HER2-positive solid tumors, potentially leading to improved and durable therapeutic responses.

The expansion phase of the trial is expected to launch in 2023. The trial will enroll a monotherapy arm with TAC01-HER2 and a combination therapy arm with TAC01-HER2 and KEYTRUDA, in patients with HER2-positive solid tumors.

Merck will supply Triumvira with KEYTRUDA for the trial and the two companies will form a Joint Development Committee to review the clinical trial results.

Further information can be found on Canada Newswire’s website.

Triumvira is a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors

MSD, known as Merck & Co., Inc., is a research-intensive biopharmaceutical company that uses the power of leading-edge science to save and improve lives around the world.